CATS-Milner Therapeutic Perspectives Series
In collaboration with CATS (the Cambridge Academy of Therapeutic Sciences), we launched the CATS-Milner Therapeutic Perspectives Series in June 2021. This panel event provides expert opinion and thought-provoking discussion around key challenges and opportunities in translational research. The series is aimed at a mixed academic-industry audience and draws on expert speakers from across academia, industry, medicine, investors, policy and funding.
Details of previous events in the series can be found below.
If you have questions about this series, please email firstname.lastname@example.org
Drug repurposing: the main challenges and solutions to fulfilling its potential
13th January, 2022
Neil Thompson, Chief Scientific Officer, Healx
Charlotte Summers, Reader in Intensive Care Medicine, University of Cambridge
Fiona Law, Partner – Patent Attorney, Potter Clarkson LLP
Namshik Han, Head of Computational Research and AI, Milner Therapeutics Institute
Catriona Crombie, Associate Director, Technology Transfer and Philanthropic Fund, LifeArc
What are the advantages and limits of new technologies providing human model systems for drug discovery?
7th October, 2021
Emma Rawlins, The Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge
Cathy Vickers, NC3Rs
Roisin Owens, Department of Chemical Engineering and Biotechnology, University of Cambridge
Victoria Marsh Durban, Cellesce
Kourosh Saeb-Parsy, Department of Surgery, University of Cambridge; CEO Avatrial
How can we make clinically meaningful progress in microbiome-related therapeutics development?
1st July 2021
Dr Mat Robinson – VP Translational Biology, Microbiotica
Dr Kiran Patil – MRC Toxicology Unit Programme Lead, University of Cambridge
Professor Denise Kelly – Investment Advisor, Seventure Partners
Professor Julian Marchesi – Professor of Digestive Health, Imperial College London
Dr Kristin Wannerberger – Director R&D Alliance Management, Ferring Pharmaceuticals
Professor Fergus Shanahan – Professor and Chair of the Department of Medicine, University College Cork
Translating breakthroughs in Alzheimer’s Disease into new treatments
10th June 2021
John Skidmore, Chief Scientific Officer, ALBORADA Drug Discovery Institute, funded by Alzheimer’s Research UK
David Rubinsztein, Cambridge Institute for Medical Research, University of Cambridge
James Rowe, MRC Cognition and Brain Sciences Unit, Department of Clinical Neurosciences, University of Cambridge
Susan Kohlhaas, Director of Research, Alzheimer’s Research UK
Peter Larsen, J&J Innovation